Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: Results from the AIR registry

Clinical and Experimental Rheumatology

Volumn 30, Issue 2, 2012, Pages 208-212

  Mekinian, Arsene ^a   Ravaud, Philippe ^b   Larroche, Claire ^c   Hachulla, Eric ^d   Gombert, Bruno ^e   Blanchard Delaunay, Claire ^f   Cantagrel, Alain ^g   Fain, Olivier ^a   Sibilia, Jean ^h   Gottenberg, Jacques Eric ^h   Mariette, Xavier ^i,j  

^a HÔPITAL JEAN VERDIER   (France)

^b HÔTEL DIEU   (France)

^c AVICENNE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e La Rochelle Hospital ^*  (France)

^f Niort Hospital   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ BICÊTRE HOSPITAL   (France)

^j INSERM   (France)

more..

Author keywords

Central nervous system involvement; Primary Sj gren's syndrome; Rituximab

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COLITIS; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DISABILITY SEVERITY; DISEASE COURSE; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; EUROPEAN SJOEGREN SYNDROME DISEASE ACTIVITY INDEX SCORE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FRANCE; HUMAN; INFUSION RELATED REACTION; MALE; MULTIPLE SCLEROSIS; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SJOEGREN SYNDROME; TREATMENT RESPONSE; WEIGHT REDUCTION; WHITE MATTER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DISABILITY EVALUATION; FEMALE; FRANCE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SJOGREN'S SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863743941     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. ALEXANDER GE, PROVOST TT, STEVENS MB, ALEXANDER EL: Sjögren syndrome: central nervous system manifestations. Neurology 1981; 31: 1931-6.
2. MASSARA A, BONAZZA S, CASTELLINO G et al: Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable-clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology 2010; 49: 1540-9.
3. DELALANDE S, DE SEZE J, FAUCHAIS AL et al.: Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine 2004; 84: 280-91.
4. PIJPE J, VAN IMHOFF GW, SPIJKERVET FK et al.: Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740-50.
5. DASS S, BOWMAN SJ, VITAL EM et al.: Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
6. SEROR R, SORDET C, GUILLEVIN L et al.: Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66: 351-7.
7. DEVAUCHELLE-PENSEC V, PENNEC Y, MORVAN J et al.: Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310-7.
8. SÈVE P, GACHON E, PETIOT P, STANKOVIC K, CHARHON A, BROUSSOLLE C: Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren's syndrome. Rheumatol Int 2007; 28: 175-7.
9. YAMOUT B, EL-HAJJ T, BARADA W, UTHMAN I: Successful treatment of refractory neuroSjögren with rituximab. Lupus 2007; 16: 521-3.
10. TOKUNAGA M, SAITO K, KAWABATA D et al.: Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-5.
11. SEROR R, RAVAUD P, BOWMAN SJ et al.; EULAR SJÖGREN'S TASK FORCE: EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103-9.
12. VINCENT TL, RICHARDSON MP, MACKWORTH-YOUNG CG, HAWKE SH, VENABLES PJ: Sjögren's syndrome-associated myelopathy: response to immunosuppressive treatment. Am J Med 2003; 1; 114: 145-8.
13. LAFITTE C, AMOURA Z, CACOUB P et al.: Neurological complications of primary Sjögren's syndrome. J Neurol 2001; 248: 577-84.
14. OZGOCMEN S, GUR A: Treatment of central nervous system involvement associated with primary Sjögren's syndrome. Curr Pharm Des 2008; 14: 1270-3.
15. ANNUNZIATA P, DE SANTI L, DI REZZE S et al.: Clinical features of Sjögren's syndrome in patients with multiple sclerosis. Acta Neurol Scand 2010; in press.
16. GOTTENBERG JE, GUILLEVIN L, LAMBOTTE O et al.; CLUB RHEUMATISMES ET INFLAMMATION (CRI): Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
17. VOULGARELIS M, GIANNOULI S, TZIOUFAS AG, MOUTSOPOULOS HM: Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006; 65: 1033-7.
18. PIJPE J, VAN IMHOFF GW, VISSINK A et al.: Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005; 64: 958-60.
19. DEVAUCHELLE-PENSEC V, MORVAN J, RAT A et al.: Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2011; 29: 6-12.
20. MEIJER JM, MEINERS PM, VISSINK A et al.: Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-8.
21. HAUSER SL, WAUBANT E, ARNOLD DL et al.; HERMES TRIAL GROUP: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. NEJM 2008; 14; 358: 676-88.
22. HAWKER K, O'CONNOR P, FREEDMAN MS et al.; OLYMPUS TRIAL GROUP: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized doubleblind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-71.